Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Opdivo plus Cabometyx reduced the risk of death by 40%.
The drug also showed promise for colorectal and other cancers, but it might work better in combination regimens.
Adding the targeted drug to chemo and radiation treatment is safe and increases the chance that most of the tumor will die before surgery.
The most aggressive type of skin cancer may respond to immunotherapy.
The targeted therapy shrank tumors in more than half of people with previously treated non-small-cell lung cancer.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
Recent studies suggest chemotherapy and immunotherapy are not linked to more severe COVID-19.
More than 80% of clinical trial participants experienced complete or partial remission.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.